DNMT3A and acute myeloid leukemia: It is revealed that AML patients with DNMT3A mutation exhibited significantly lower AdaptAge and elevated DamAge compared to non‐carriers, both indicating adverse DNAm changes (Figure 2B), indicative of a disrupted balance between protective epigenetic mechanisms and accumulating damage.